Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: City of Hope, Duarte, California +63 locations
Conditions: Metastatic Non Small Cell Lung Cancer
Tight Control of Gouty Arthritis Compared to Usual Care
Recruiting
Gout is caused by a reaction to urate crystals that results in attacks of severe joint pain. Medicines that lower urate levels can prevent gout flares, however it takes time for this benefit to be felt, and paradoxically starting treatment with large doses of urate lowering treatment risks provoking attacks of gout. Medical guidelines disagree on the best way to overcome these challenges with many recommending medicine dose adjustment based on regular urate testing but a general practice guideli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: NHS Lothian, Edinburgh, Not set
Conditions: Gout
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
Recruiting
This is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System and the Edwards PASCAL Precision Transcatheter Valve Repair System in transcatheter mitral valve repair.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Medizinische Universität Wien/AKH Wien, Wien, Not set +36 locations
Conditions: Mitral Regurgitation, Mitral Insufficiency
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Recruiting
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/25/2025
Locations: UCSD Altman Clinical and Translational Research Institute Building, La Jolla, California +17 locations
Conditions: Neuromyelitis Optica Spectrum Disorder
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
Recruiting
The investigators present a diet intervention study, to be conducted as a within-subject design, to assess the effect of the provision of iron biofortified microgreens on iron intake and status in women of reproductive age and postmenopausal women. This will be investigated by providing smoothie kits for 28 days containing these microgreens and determining the impact on iron biomarkers. The investigators will also assess habitual diet, BMI, physical activity and gastrointestinal symptoms. This s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Rowett Institute, University of Aberdeen, Aberdeen, Not set
Conditions: Iron Biomarkers/Status
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Recruiting
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/25/2025
Locations: University of Cincinnati, Cincinnati, Ohio +8 locations
Conditions: Prevention of Rejection in Kidney Transplant
CBT and the Neural Circuits of Anxiety
Recruiting
This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted/specific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate a... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/25/2025
Locations: Institute of Cognitive Neuroscience, University College London, London, Not set
Conditions: Generalised Anxiety Disorder, Anxiety Disorders, CBT, Anxiety Depression, Anxiety Disorders and Symptoms, Anxiety Generalized, Anxiety, Anxiety Disorder Generalized, Anxiety Disorder; Mixed With Depression (Mild)
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Recruiting
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/25/2025
Locations: Sydney children Hospital, Sydney, Randwick +141 locations
Conditions: High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Southern Cancer Center Pc, Daphne, Alabama +246 locations
Conditions: Metastatic Non Small Cell Lung Cancer
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants
Recruiting
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), and healthy participants of Chinese and Japanese descent (Part C).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/25/2025
Locations: GSK Investigational Site, Cambridge, Not set
Conditions: Systemic Lupus Erythematosus
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +849 locations
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Recruiting
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Research Site, Jacksonville, Florida +24 locations
Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma